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he National Institutes of Health (NIH) is a complex organization with 27 Insti-
tutes and Centers (ICs). As one of four programmatic offices within the NIH 
Office of the Director, the mission of the Office of Behavioral and Social Sci-
ences Research (OBSSR) is to coordinate and stimulate behavioral and social science 
research across all NIH institutes and centers. Since OBSSR does not fund research 
directly, collaboration with the ICs is crucial. Although OBSSR is not in a position to 
control what individual IC directors may choose to fund or focus upon, behavioral 
and social science activity is common across the ICs, - both in terms of basic research 
on behavioral and social mechanisms affecting health, and translational research on 
converting knowledge into practice.  
In addition to OBSSR’s coordinating 
role, members of an NIH-wide behav-
ioral and social science research coordi-
nating committee meet monthly to keep 
one another informed and to streamline 
and leverage their var-
ious activities, as need-
ed. 
How much behav-
ioral and social science 
research actually takes 
place at NIH? OBSSR 
is exploring this ques-
tion more systematical-
ly and in some detail, 
but until that analysis is completed, a 
reasonable estimate might be around 11-
12 percent of the total NIH budget. Alt-
hough all the ICs report at least some 
behavioral and social science activity, 
the National Institute on Mental Health 
(NIMH) is the biggest player, followed 
by the National Institute of Drug Abuse 
(NIDA), the National Institute on Child 
Health and Development (NICHD), the 
National Institute on Aging (NIA), NI-
AAA, and the National 
Cancer Institute (NCI) 
(See Figure 1). 
OBSSR’s priorities 
need to be aligned and 
coordinated with those 
of NIH overall and the 
broader notions of 
health are embedded in 
NIH’s mission state-
ment. In particular, five opportunities 
for research at NIH that Dr. Collins pre-
sented in a Science article (Collins 2010) 
soon after he assumed the NIH Director 
role: 
• High-throughput technologies; 
T 
NIH Mission Statement 
NIH’s mission is to seek fun-
damental knowledge about the 
nature and behavior of living 
systems and the application of 
that knowledge to enhance 
health, lengthen life, and reduce 
the burdens of illness and disa-
bility.
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• Translational medicine; 
• Benefitting health care reform; 
• Focusing more on global health; 
and 
• Reinvigorating and empowering 
the biomedical research com-
munity. 
Some of the work is already under-
way at OBSSR and elsewhere within 
NIH. Specific opportunities include: 
Back to basics 
OBSSR is home to the NIH-wide 
OppNet program, which represents a 
significant and ongoing investment in 
strengthening the relationship between 
basic biomedical and behavioral/social 
science research across the agency. 
Taking advantage of current and 
future innovation 
While high-throughput technology 
has not been a major focus of activity 
(yet), gene-environment interaction 
(GEI) is — and promises to be even more 
so in the future. OBSSR is active in the 
GEI area by linking the exposure biology 
program (which is developing technolo-
gies and biomarkers for tracking diet, 
physical activity, environmental expo-
sures, psychosocial stress and addictive 
substances) with research on genetic var-
iants.  
Current OBSSR and NCI-funded re-
search being conducted by Kevin Patrick 
at UC San Diego on the “exposome” — a 
concept comparable to the human ge-
nome, but that measures instead the ex-
posures (including lifestyle factors as 
well as environmental ones) that a hu-
man experiences across the life course 
and explores the relationships between 
these exposures and disease (Wild 2005). 
In many respects, measuring genotypes 
is fairly straightforward, compared to 
the dynamic, lifelong exposures that 
evolve continuously, starting in utero 
and continuing through childhood, ado-
lescence, adulthood and old age. Gene 
and environmental exposure should be 
considered together, but currently 
there’s an imbalance in the tools for 
measurement. 
With the widespread adoption of 
mobile phone technology (currently at 5 
billion users worldwide and expected to 
quadruple to 20 billion within the next 
decade) and applications for phones and 
other devices, changes in how health is 
portrayed, measured, and understood 
will follow.  
Certainly, there is justifiable skepti-
cism that some new apps will merely 
offer glitzier versions of “old school” 
(and ineffective) health education mes-
sages. Still, the technology is likely to 
change very rapidly, offering potential 
uses we can’t even envision yet. For ex-
ample, some basic cell phone apps exist 
that allow an individual to take an over-
head picture of a plate of food at a meal, 
and estimate the intake of protein, car-
bohydrates, fat, etc. (Borrell 2011). The 
technology is crude at the moment, but 
won’t be for long — new iterations are 
already in development. Similarly, sen-
sors and nanotechnology are already 
becoming feasible means of capturing 
and relaying information in real time — 
such as merging GPS and activity data to 
determine which park features support 
the most physical activity.  
The point is that we have to think 
ahead, and try to imagine where the re-
search will be in 15 or 20 years. “Will we 
have the right technologies?” “Are we 
thinking far enough ahead?” OBSSR is 
trying to think ahead in a number of 
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ways, considering the implications for 
new research designs, new methods of 
data fusion and synthesis, new genera-
tions of health data analysts, and new 
approaches to handling the privacy of 
health-related information and health 
data security. Specific OBBSR activities 
and partnerships in these areas include a 
Systems Science Institute conference 
held in Pittsburg in May 2011, mHealth 
with Qualcomm in June 2011, a “Big Da-
ta” initiative on data visualization, and 
exploring ways to harmonize psychoso-
cial information in EMRs. 
Informing public policy 
Benefitting health care reform was 
another item on Dr. Collins’s “opportu-
nities” list; he would like to see NIH 
more involved in presenting evidence-
based opinion that could provide in-
sights for public policy. This represents a 
new direction for NIH, which typically 
has shied away from public policy re-
search. For OBSSR, which is a natural 
home for these activities, it has meant 
participating actively in a CMS working 
group and becoming more involved in 
partnerships with the Centers for Dis-
ease Control and Prevention (CDC). 
One area of interest is the negative 
relationship between the quality of 
health care and Medicare spending. Io-
wa, for example, is on the low end of 
expenditures but the high end of quality, 
while California spends nearly the most 
yet achieves the very low quality in rela-
tion to other states. As an example, con-
sider my two former hometowns in 
southern California, just 100 miles apart: 
Los Angeles and San Diego. The Medi-
care program spends an average of 
$11,300 for each recipient in Los Ange-
les, in comparison to $8,500 in San Diego 
(Kaplan 2011). To illustrate how the im-
portance $2,800 difference in expendi-
tures could be in two communities shar-
ing such geographic proximity, consider 
the cost of a Lexus ES 300 — a luxury car 
that currently retails for just under 
$52,000. The car’s cost represents the dif-
ference in median Medicare costs be-
tween Los Angeles and San Diego coun-
ties (based on Dartmouth Atlas data) for 
a 65-year-old with a projected 18.6-year 
life expectancy from that point forward 
($2800 x 18.6 years = $52,080). Simple 
calculations suggest that you could af-
ford to buy a brand-new Lexus for every 
Medicare recipient in Los Angeles (1.3 
million people) if they would accept the 
medical care one gets in San Diego in-
stead. Getting more for less, and getting 
higher health care quality at lower costs, 
are questions to pursue and document. 
Answering the dissemination  
challenge 
Although we spend billions to cre-
ate the next generation of therapies and 
cures, we spend a very small proportion 
of that investment — as little as $.01 for 
every $1 — on learning how to dissemi-
nate those same treatments (Woolf and 
Johnson 2005). For example, treatment of 
high blood pressure to control hyperten-
sion is an area we can take pride in.  
According to NHANES data from 
2004, awareness of hypertension among 
those with high blood pressure reached 
80 percent (Egan, Zhao et al. 2010). But 
only 70 percent of these patients were in 
treatment, and only 30 percent had their 
blood pressure under control. The latest 
data show some improvement, with con-
trol as high as 50 percent. However, 
even in this scenario, if 80 percent are 
aware, 70 percent are under treatment, 
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and 50 percent of patients have their 
high blood pressure under control, this 
“improved” level of control still means 
that only 28 percent of those with high 
blood pressure are successfully treated. 
We know from clinical studies that al-
most anyone can have his or her blood 
pressure controlled: It’s a problem of 
dissemination. 
Comparisons of investments in 
tweaking molecules versus dissemina-
tion show a far greater return on in-
vestment for investments in dissemina-
tion. For example, office reminders for 
cholesterol treatments were estimated to 
prevent seven times more deaths than 
replacing older cholesterol-lowering 
drugs with more potent versions of the 
drugs (Woolf and Johnson 2005). 
To support dissemination and trans-
lation research, OBSSR is sponsoring 
conferences, training institutes, and 
trans-NIH Funding Opportunity An-
nouncements (FOAs) that highlight dif-
ferent aspects of dissemination, transla-
tion, and implementation. 
Going global 
Global health issues are another op-
portunity on Dr. Collins’s list. Although 
life expectancy for females has increased 
steadily in developing countries since 
1960, life expectancy increases for wom-
en in the United States are not keeping 
pace with the rest of the world, with the 
United States now ranked 47th 
(Crimmins, Preston et al. 2011). OBSSR is 
working with the National Academy of 
Sciences and Institute of Medicine on a 
project to explore international health 
differences in high-income countries and 
identify public health opportunities. The 
Office values global health, recognizing 
the importance of global health in an in-
creasingly interconnected world. More 
specifically, behavioral and social sci-
ence research clearly has a significant 
role to play in reducing the global bur-
den of disease. OBSSR is active in sever-
al workforce and research training initia-
tives in Africa, most recently convening 
a week-long institute in South Africa 
that brought together 45 researchers 
from 13 sub-Saharan countries. 
While OBSSR has been active in 
each of these areas and will continue to 
be, we also want to think about what the 
world — and science — will look like in 
the next decade or two, and how we can 
best prepare for it. Discussions with 
leaders of academic research institutions 
and with faculty research innovators 
will help guide future NIH policy and 
research agendas. 
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